Geron (GERN) Stock Forecast & Price Target

Geron is supported by a lead asset, Rytelo (imetelstat), that has already achieved approval in the U.S. and European Union for lower-risk myelodysplastic syndromes with transfusion-dependent anemia, giving the company a tangible commercial base rather than a purely developmental profile. Recent execution appears constructive, with 2Q:26 revenue of $57.5M, 11% sequential growth, ordering accounts up about 8% to 1,575, and gross-to-net in the low 20% range, while management pointed to the mid to high end of its $220-240M full-year guidance. Even with MF removed from the model after IMpactMF discontinuation, the outlook remains favorable because the lack of new safety signals preserves physician confidence, NCCN preferred status supports uptake, and upcoming IST readouts provide additional upside drivers.

Geron is facing a major setback after the Phase 3 IMpactMF trial was discontinued following an independent DMC recommendation that it was unlikely to meet its overall survival endpoint, eliminating a key growth driver in myelofibrosis and forcing removal of MF revenue from the model. The decision was not driven by new safety signals, but it does underscore the difficulty of translating the smaller Phase 2 MYF2001 signal into a registrational success, especially as the best available therapy backdrop appears to have improved over time. With the stock now more dependent on execution in LR-MDS, the outlook remains negative because concentration risk is high and the remaining commercial opportunity may not be enough to offset the lost MF upside.